Los Angeles Capital Management LLC Lowers Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Los Angeles Capital Management LLC lessened its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 44.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,528 shares of the company's stock after selling 44,473 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.08% of Kiniksa Pharmaceuticals worth $1,098,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Wellington Management Group LLP bought a new position in shares of Kiniksa Pharmaceuticals during the third quarter valued at $1,192,000. JPMorgan Chase & Co. acquired a new stake in Kiniksa Pharmaceuticals in the third quarter valued at $4,997,000. Parkman Healthcare Partners LLC raised its position in Kiniksa Pharmaceuticals by 16.7% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company's stock worth $18,874,000 after purchasing an additional 108,102 shares during the last quarter. Segall Bryant & Hamill LLC acquired a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth about $675,000. Finally, SG Americas Securities LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at about $355,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the transaction, the chief operating officer now owns 81,975 shares of the company's stock, valued at $1,604,250.75. This represents a 14.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 29,123 shares of company stock valued at $553,204. Corporate insiders own 54.57% of the company's stock.

Remove Ads

Kiniksa Pharmaceuticals Trading Up 0.3 %

NASDAQ KNSA traded up $0.06 during trading hours on Wednesday, hitting $21.39. 1,238,130 shares of the company's stock were exchanged, compared to its average volume of 622,915. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -152.77 and a beta of 0.32. The stock has a 50-day simple moving average of $19.70 and a 200 day simple moving average of $22.41. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $16.56 and a 1-year high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same period last year, the business earned $0.35 EPS. The business's quarterly revenue was up 46.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KNSA has been the topic of a number of recent analyst reports. Wedbush reaffirmed an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. JPMorgan Chase & Co. upped their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $36.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.